Striking Weight Loss Seen With Combo Drug in Diabetes Trial
The highest-dose combination also lowered A1C more, but up to 27% of patients stopped treatment because of side effects.
10 Articles
10 Articles
Pharmaceutical companies compete for the development of increasingly powerful molecules to treat obesity, but is there a limit?
Kreiszeitung
In a study in people with overweight or obesity and type 2 diabetes, participants with a new combination of two active substances lost an average of up to 23.3 percent of their weight within 48 weeks.
Striking Weight Loss Seen With Combo Drug in Diabetes Trial
(MedPage Today) -- Adults with type 2 diabetes achieved impressive weight loss with an investigational combination agent of eloralintide plus tirzepatide (Mounjaro, Zepbound), according to a phase IIb study. In the 10-arm trial, participants on...
A new combination of eloralintide and tirzepatide produced greater estimated weight loss than tirzepatide alone in a phase 2b study. In the combination groups, up to 27 percent discontinued treatment due to side effects.
Coverage Details
Bias Distribution
- 87% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
